[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.247.205. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
November 16, 2011

Rational Dispersion for the Introduction of Transcatheter Valve Therapy

Author Affiliations

Author Affiliations: Society of Thoracic Surgeons, Plano, Texas (Dr Mack); and American College of Cardiology, Rochester, Minneapolis (Dr Holmes).

JAMA. 2011;306(19):2149-2150. doi:10.1001/jama.2011.1675

Complex, high-risk medical devices ordinarily receive regulatory approval for use in clinical practice based on results from rigorous randomized controlled trials (RCTs). However, the trial results obtained in a specific population in select centers by expert health care teams and with limited long-term follow-up may not be generalizable in the “real-world setting.” To assess this latter issue, once the device is approved, the Food and Drug Administration (FDA) typically requires postmarketing surveillance studies to detect safety issues in the broader application of the device in expanded, community use.

First Page Preview View Large
First page PDF preview
First page PDF preview
×